ETANA PARTNERS WITH DEG IMPULSE TO STRENGTHEN DIGITAL TRANSFORMATION OF VACCINE PRODUCTION IN INDONESIA

Jakarta, 30 September 2025 - PT Etana Biotechnologies Indonesia (Etana) has officially signed a strategic partnership with DEG Impulse, a subsidiary of DEG - Deutsche Investitions- und Entwicklungsgesellschaft mbH, to implement a digital transformation of the company’s core quality management system. This initiative aims to increase vaccine production capacity, strengthen regulatory compliance and enhance national health system resilience.

This collaboration aligns with the Indonesian government’s efforts to strengthen the national pharmaceutical industry, reduce import dependency and improve access to healthcare services. Through the Digital Indonesia Roadmap 2021–2024, the government is also driving digital transformation in the healthcare and pharmaceutical sectors. The project supports this priority by establishing a more integrated digital quality system, thereby improving health resilience, pandemic preparedness and industrial self-reliance. Etana and DEG Impulse are working together within the framework of the develoPPP funding programme, which DEG Impulse implements on behalf of the German Federal Ministry

for Economic Cooperation and Development (BMZ). DEG had already provided Etana with equity financing in 2023.

“We truly appreciate the support provided by DEG Impulse for this project. As the only mRNA vaccine manufacturer in Southeast Asia, Etana is ready to advance transformation efforts toward stronger pandemic preparedness, enhanced compliance with cGMP standards, and improved supply chain agility. With this support, we can continue to grow as a key player and contribute to strengthening national health resilience,” said Nathan Tirtana, President Director of Etana.

“This project is the result of a partnership built on trust and credibility. I’m proud to be here, signing this agreement and witnessing how the initiative is driving Etana’s transformation while also making a meaningful contribution to improving healthcare,” said Marco Christ, Managing Director of DEG Impulse.

Additional support came from Benjamin Knoedler, Head of Private Sector Engagement at the German Federal Ministry for Economic Cooperation and Development, who highlighted the critical role of the private sector in development.

“It is the private sector that creates jobs and drives the economy. We truly value joining forces with the private sector in advancing both business and development. This project is a role model for a successful collaboration of the private sector and international development cooperation,” said Benjamin.

Through this project, Etana will enhance operational efficiency, improve product quality, and adopt digital transformation in quality management to deliver accurate data and enable data-driven decision-making. In addition, more than 200 employees will be trained in GxP principles, digital compliance, and cybersecurity, with 100 key personnel certified in system operations, and the creation of 10 new permanent jobs.

This milestone underscores Etana’s commitment to delivering high-quality and affordable healthcare solutions, supporting both national and regional health resilience, while contributing to the achievement of the Sustainable Development Goals (SDGs).

About DEG Impulse

DEG Impulse is a 100 % non-profit subsidiary of the German Development Finance Institution DEG - Deutsche Investitions- undEntwicklungsgesellschaft mbH. DEG Impulse promotes the sustainable transition of the private sector in developing and emerging-market countries and supports development policy goals as defined by the Sustainable Development Goals. Via our advisory and promotional programmes we support the transformation process of companies and enable them to implement their projects efficiently and effectively, in order to generate both commercial success and development-policy benefits.

 About Etana

Established in 2014, Etana is an Indonesian biopharmaceutical company that manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.